Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Efient

Sanofi reception

Poor Lantus sales sees Sanofi’s diabetes unit fall

French firm hit by insulin pricing pressures and soon faces biosimilar threat

- PMLiVE

Is a UK market access shake-up on the cards?

Former coalition government health minister Paul Burstow tells PMLiVE that NICE, QALY and broader issues of market access in England are all being put under review

- PMLiVE

BMS gives Erbitux rights to Lilly in the US

Firm wants to focus on its burgeoning PD-1 cancer range

Gilead Sciences

Sovaldi pushes Gilead to the top of US pharma list

Blockbuster hep c pill sees the firm go from fourteenth to first in just one year

National Institute for Health and Care Excellence NICE logo

UK market access issues put on hold during election

NICE appraisals and Cancer Drugs Fund appeals will not be undertaken until May

- PMLiVE

Pfizer and Pharmacy Voice launch NHS campaign

Campaign aims to reduce inappropriate use of A&E services 

- PMLiVE

Final NICE ‘no’ for Celgene’s Imnovid

England’s pricing watchdog says multiple myeloma drug is just too expensive for the NHS

Seismic shifts: Hepatitis C and payers

How hep C is causing paradigm changes in payer behaviour

- PMLiVE

Lilly/Boehringer’s diabetes combination Glyxambi debuts in US

Companieslaunch first fixed-dose of empagliflozin and linagliptin

Eli Lilly HQ

Pfizer and Lilly restart tanezumab pain trials

FDAlifts clinical block on late-stage studies of the novel painkiller

Eli Lilly HQ

Lilly signs cancer pact with Chinese biotech

Marks first major deal between a Western pharma company and a Chinese biotech

- PMLiVE

AZ and Daiichi Sankyo sign Movantik marketing deal

Two firms have agreed the deal for the new constipation pill

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links